For example, the humanized recombinant EDA-A1 protein EDI200 has shown efficacy to improve HED [13], and EDAR is thought to be a promising druggable target for inhibiting carcinogenesis [9,10]. The gene discussed is EDA; the disease is hypohidrotic ectodermal dysplasia.